Literature DB >> 19296404

Prevalence of antibodies against Chlamydia trachomatis and incidence of C. trachomatis-induced reactive arthritis in an early arthritis series in Finland in 2000.

E Savolainen1, A Kettunen, A Närvänen, H Kautiainen, U Kärkkäinen, R Luosujärvi, O Kaipiainen-Seppänen.   

Abstract

OBJECTIVE: To study the prevalence of different serotypes of Chlamydia trachomatis antibodies and the incidence of C. trachomatis-induced reactive arthritis (ReA) among patients with early arthritis in a defined population.
METHODS: Serum samples were collected from a cohort of 122 adult patients in the age group 18-65 years included in the Kuopio 2000 Arthritis Survey. Antibodies against C. trachomatis serotypes C, E, and G were studied using enzyme immunoassay (EIA) tests among patients and in a control cohort of 78 adults without any joint symptoms. The incidence assessment for Chlamydia-induced ReA was based on a ligase chain reaction (LCR) test in urine and clinical symptoms and signs appropriate for ReA.
RESULTS: Of 122 patients, with the baseline diagnosis of rheumatoid arthritis (RA) in 11, spondyloarthropathy (SpA) in 28, and undifferentiated arthritis (UA) in 83 cases, 42 (34%) showed immunoglobulin (Ig)G or IgA antibodies against at least one serotype C, E, or G. Among the patients with UA the prevalence was significantly increased compared with the controls (p = 0.010). C. trachomatis-induced ReA arthritis was diagnosed in only three patients with the LCR test. On this basis the incidence of C. trachomatis-induced arthritis was 5.4/100 000 [95% confidence interval (CI) 1.1-15.7] in the age group 18-65 years.
CONCLUSION: Antibodies against C. trachomatis were most common in patients with UA reflecting the fact that cases with chlamydia-induced ReA are included in this subgroup.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296404     DOI: 10.1080/03009740902769559

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

Review 1.  Undifferentiated spondyloarthritis: recent clinical and therapeutic advances.

Authors:  Vanesa Cruzat; Raquel Cuchacovich; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

2.  Association between intracellular infectious agents and Tourette's syndrome.

Authors:  Daniela Krause; Judith Matz; Elif Weidinger; Jenny Wagner; Agnes Wildenauer; Michael Obermeier; Michael Riedel; Norbert Müller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11-05       Impact factor: 5.270

Review 3.  Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research.

Authors:  Henning Zeidler; Alan P Hudson
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

4.  Incidence of Chlamydia trachomatis infection in patients with reactive arthritis.

Authors:  Iwona Ostaszewska-Puchalska; Bożena Zdrodowska-Stefanow; Anna Kuryliszyn-Moskal; Violetta Bułhak-Kozioł; Marianna Sokołowska
Journal:  Reumatologia       Date:  2015-05-18

5.  Spondyloarthritis, Acute Anterior Uveitis, and Fungi: Updating the Catterall-King Hypothesis.

Authors:  Martin Laurence; Mark Asquith; James T Rosenbaum
Journal:  Front Med (Lausanne)       Date:  2018-04-05

Review 6.  Recent Developments in HLA B27 Anterior Uveitis.

Authors:  Denis Wakefield; Daniel Clarke; Peter McCluskey
Journal:  Front Immunol       Date:  2021-01-05       Impact factor: 7.561

Review 7.  [Postinfectious reactive arthritis after chlamydia infection in competitive sports : Clinical management and current literature review].

Authors:  Sebastian Klingebiel; Horst Rieger; Georg Gosheger; Jan Christoph Theil; Carolin Rickert; Kristian Nikolaus Schneider
Journal:  Orthopade       Date:  2021-03       Impact factor: 1.087

8.  Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach.

Authors:  Anukriti Verma; Shivani Sharda; Bhawna Rathi; Pallavi Somvanshi; Bimlesh Dhar Pandey
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.